Canaccord analyst John Newman raised the firm’s price target on Cartesian Therapeutics to $43 from $38 and keeps a Buy rating on the shares after the company reported that the Phase 2b DESCARTES-08 study in Myasthenia Gravis achieved its primary endpoint. The firm raised its price target based on greater confidence in Phase 3 success for DESCARTES-08 and now assumes a 50% chance of success, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik
- Cartesian Therapeutics: Investment, Director Appointment, and Trial Success
- Cartesian Therapeutics announces $130M private placement equity financing
- Cartesian says first patient dosed in Phase 2 trial of Descartes-08 in SLE
- Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis